Skip to content
News & Publications
News
Publications
Contact Us
About Us
History
Patents
Technology
Signaling Chain HOmoOLigomerization (“SCHOOL”) Platform Basics
Macrophage Modulation
Macrophage Imaging
Pipeline
Therapeutic Areas
Cancer
Autoimmune Diseases
Retinopathy
Atherosclerosis
Sepsis/ARDS & COVID
Other Inflammatory Diseases
Partners & Collaborators
Menu
Understanding Nature. Improving Life
Type and press enter to search
SignaBlok awarded NCI / NIH SBIR Phase I grant to test TREM-1 therapy for pancreatic cancer
SignaBlok
>
News
>
SignaBlok awarded NCI / NIH SBIR Phase I grant to test TREM-1 therapy for pancreatic cancer
SignaBlok
>
News
>
SignaBlok awarded NCI / NIH SBIR Phase I grant to test TREM-1 therapy for pancreatic cancer
SignaBlok awarded NCI / NIH SBIR Phase I grant to test TREM-1 therapy for pancreatic cancer
Post navigation
Previous Post
SignaBlok presented preclinical data showcasing company’s peptide therapeutic programs in cancer, inflammation and autoimmune diseases at the 2015 Therapeutics Stream at the Essential Protein Engineering Summit (PEGS) Annual Meeting
Next Post
SignaBlok presented proof-of-concept animal data on development of a novel targeted treatment for rheumatoid arthritis at the 2015 ACR Annual Meeting
Vera
View posts by Vera
Scroll to top
close ×
